The article reports the results of the international multicenter study EMPEROR-Reduced that have been announced at the online expert meeting. Considering the positive cardiovascular and renal effects of empagliflozin, the experts have supported the use of empagliflozin in clinical practice to treat patients with chronic heart failure. |
Online First. The resolution on empagliflozin and heart failure has been adopted by the experts of the Siberian Federal District based on the results of the EMPEROR-Reduced study
Popular articles
Vol 11, No 4 (2022)
No 3 (2015)
No 1 (2015)
Vol 9, No 2 (2020)
Keywords
Acute coronary syndrome
Arterial hypertension
Atherosclerosis
Atrial fibrillation
COVID-19
Cardiovascular diseases
Children
Congenital heart defects
Coronary artery bypass grafting
Coronary artery disease
Heart failure
Myocardial infarction
Risk factors
acute coronary syndrome
acute myocardial infarction
arterial hypertension
coronary artery bypass grafting
coronary artery disease
myocardial infarction
percutaneous coronary intervention
risk factors
Research Institute for Complex Issues of Cardiovascular Diseases
6, Sosnoviy Blvd., 650002, Kemerovo, Russian Federation
Tel.: 8 (3842) 34-53-89; tel./fax: 8 (3842) 34-53-89
E-mail: avtor@kemcardio.ru
